Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients

Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population...

Source: The Rheumatologist - February 19, 2020 Category: Rheumatology Authors: Lara C. Pullen, PhD Tags: Conditions Crystal Arthritis Gout SGLT2 inhibitors sodium-glucose cotransporter-2 (SGLT2) inhibitors type II diabetes Source Type: research